Published • loading... • Updated
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
Summary by MarketBeat
1 Articles
1 Articles
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritizat
·Sioux Falls, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
